Merck announces winner of 2014 Emerging Biotech Grant Program
Issue: March 24, 2015
| Category: Upstream, Downstream
Committed to helping advance lifesaving drugs to market, Merck hosted its first emerging biotech grant program last year, awarding one company up to $89,000 in products and services to help develop their molecule.
NGM Biopharmaceuticals, Inc. was selected as the 2014 recipient. The company, based in San Francisco, was chosen in accordance with the contest rules. Decision-making criteria included the scientific and societal merit of the therapy being developed, and process challenges and expertise gaps associated with the development of the therapy.
NGM Biopharmaceuticals, is an innovative drug discovery company engaged in identifying and developing biologics for the treatment of cardio-metabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardio-metabolic abnormalities and metabolic related cancers. It is our hope that with the use of Merck's tools and services, we will be able to help advance the manufacturing of their biologics.
Remaining committed to the Emerging Biotech market, Merck is hosting an exclusive Emerging Biotech Executive Summit this June where industry and Merck executives will network and join panel discussions around Perspectives on Early Stage Investments and Partnerships, and Building Value, Credibility and Recognition on the Road to Clinic.
In This Same Issue: